Polyphyllin II inhibits breast cancer cell proliferation via the PI3K/Akt signaling pathway
Molecular Medicine Reports · 2024
DOI: 10.3892/mmr.2024.13348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Medicine Reports, 2024. Verfasst von Weiwei Miao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Breast Neoplasms, Signal Transduction, Cell Proliferation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Paridis Rhizoma saponins (PRS) are significant components of Rhizoma Paridis and have inhibitory effects on various tumors, such as bladder, breast, liver and colon cancer. Polyphyllin II (PPII), one of the PRS, has an unclear effect on breast cancer. The present study aimed to explore the effect and mechanism of PPII in breast cancer. A network pharmacology approach was employed to predict the core components and breast cancer‑related targets of PRS. Moreover, a xenograft tumor model was established to determine the anti‑breast cancer effect of PPII in vivo. The viability of MDA‑MB‑231 cells was determined by a Cell Counting Kit‑8 assay. Apoptosis was analyzed using annexin V/PI double staining. Additionally, Transwell and scratch assays were performed to evaluate invasion and migration. The potential mechanism was predicted by Kyoto Encyclopedia of Genes and Genomes enrichment analysis and molecular docking analysis and verified by western blot analysis. The effect of PPII on aerobic glycolysis in breast cancer cells was detected by lactic acid and pyruvate kits and Western blotting of glycolytic rate‑limiting enzymes. Network pharmacology analysis revealed 26 core targets involved in breast cancer and that PPII was the core active component of PRS. The in vivo studies showed that PPII could inhibit the growth of breast cancer in mice. In vitro experiments confirmed that PPII induced cancer cell apoptosis and inhibited invasion and migration. Furthermore, PPII was capable of suppressing the expression of key proteins in the PI3K/Akt signaling pathway, reducing the generation of aerobic glycolytic products, and diminishing the protein expression levels of hexokinase 2 and pyruvate kinase M2. The results indicated that PPII inhibited aerobic glycolysis in breast cancer cells through the PI3K/Akt signaling pathway, thereby inhibiting breast cancer growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Science, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan.
- College of Health Management, Shanghai Jian Qiao University, Shanghai 201306, P.R. China.
Zitieren
APA
Miao, W., Wang, Z., Gao, J., & Ohno, Y. (2024). Polyphyllin II inhibits breast cancer cell proliferation via the PI3K/Akt signaling pathway. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2024.13348
Vancouver
Miao W, Wang Z, Gao J, Ohno Y. Polyphyllin II inhibits breast cancer cell proliferation via the PI3K/Akt signaling pathway. Molecular Medicine Reports. 2024. doi:10.3892/mmr.2024.13348
BibTeX
@article{Miao2024,
author = {Miao, Weiwei and Wang, Zhixiong and Gao, Jianwen and Ohno, Yuko},
title = {Polyphyllin II inhibits breast cancer cell proliferation via the PI3K/Akt signaling pathway},
journal = {Molecular Medicine Reports},
year = {2024},
doi = {10.3892/mmr.2024.13348}
}
EUVIMED